Annotation (Toggle Detail/Summary View) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene-Chemical Interaction Annotations
Gene-Chemical Interaction AnnotationsTerm | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 17beta-estradiol | affects expression | ISO | RGD:731453 | 6480464 | Estradiol affects the expression of MYO5A mRNA | CTD | PMID:22574217 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:731454 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MYO5A mRNA | CTD | PMID:19465110 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:731454 | 6480464 | Tetrachlorodibenzodioxin affects the expression of MYO5A mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:731454 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MYO5A mRNA | CTD | PMID:19465110 PMID:21354282 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:731454 | 6480464 | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to MYO5A promoter] | CTD | PMID:19654925 | all-trans-retinoic acid | multiple interactions | ISO | RGD:731453 | 6480464 | [Tretinoin co-treated with Tamoxifen] results in increased expression of MYO5A protein | CTD | PMID:17098229 | all-trans-retinoic acid | increases expression | ISO | RGD:731453 | 6480464 | Tretinoin results in increased expression of MYO5A protein | CTD | PMID:17098229 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of MYO5A mRNA | CTD | PMID:16483693 | ammonium chloride | increases expression | EXP | | 6480464 | Ammonium Chloride results in increased expression of MYO5A protein | CTD | PMID:16483693 | asbestos | affects expression | ISO | RGD:731453 | 6480464 | Asbestos affects the expression of MYO5A mRNA | CTD | PMID:17297452 | benzo[a]pyrene | increases expression | ISO | RGD:731454 | 6480464 | Benzo(a)pyrene results in increased expression of MYO5A mRNA | CTD | PMID:22228805 | calcium atom | affects activity | ISO | RGD:731454 | 6480464 | Calcium affects the activity of MYO5A protein | CTD | PMID:10660602 | calcium(0) | affects activity | ISO | RGD:731454 | 6480464 | Calcium affects the activity of MYO5A protein | CTD | PMID:10660602 | chlorambucil | increases mutagenesis | ISO | RGD:731454 | 6480464 | Chlorambucil results in increased mutagenesis of MYO5A gene | CTD | PMID:10517996 | chlorpyrifos | increases expression | ISO | RGD:731454 | 6480464 | Chlorpyrifos results in increased expression of MYO5A mRNA | CTD | PMID:20350560 | choline | multiple interactions | ISO | RGD:731454 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MYO5A mRNA | CTD | PMID:20938992 | cobalt dichloride | decreases expression | ISO | RGD:731453 | 6480464 | cobaltous chloride results in decreased expression of MYO5A mRNA | CTD | PMID:19320972 | cocaine | increases expression | EXP | | 6480464 | Cocaine results in increased expression of MYO5A mRNA | CTD | PMID:17898221 | copper atom | multiple interactions | ISO | RGD:731453 | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MYO5A mRNA | CTD | PMID:20971185 | copper(0) | multiple interactions | ISO | RGD:731453 | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MYO5A mRNA | CTD | PMID:20971185 | coumestrol | multiple interactions | ISO | RGD:731453 | 6480464 | [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO5A mRNA; more ... | CTD | PMID:19167446 | coumestrol | decreases expression | ISO | RGD:731453 | 6480464 | Coumestrol results in decreased expression of MYO5A mRNA | CTD | PMID:19167446 | diazoxide | increases expression | ISO | RGD:731454 | 6480464 | Isoproterenol results in increased expression of MYO5A mRNA | CTD | PMID:20003209 | folic acid | multiple interactions | ISO | RGD:731454 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MYO5A mRNA | CTD | PMID:20938992 | isoprenaline | increases expression | ISO | RGD:731454 | 6480464 | Isoproterenol results in increased expression of MYO5A mRNA | CTD | PMID:20003209 | L-methionine | multiple interactions | ISO | RGD:731454 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MYO5A mRNA | CTD | PMID:20938992 | N-ethyl-N-nitrosourea | increases mutagenesis | ISO | RGD:731454 | 6480464 | Ethylnitrosourea results in increased mutagenesis of MYO5A gene | CTD | PMID:17174358 more ... | N-ethyl-N-nitrosourea | increases mutagenesis | ISO | RGD:731454 | 6480464 | Ethylnitrosourea results in increased mutagenesis of MYO5A gene | CTD | PMID:10517996 more ... | N-ethyl-N-nitrosourea | increases mutagenesis | ISO | RGD:731454 | 6480464 | Ethylnitrosourea results in increased mutagenesis of MYO5A gene | CTD | PMID:10517996 more ... | N-ethyl-N-nitrosourea | increases mutagenesis | ISO | RGD:731454 | 6480464 | Ethylnitrosourea results in increased mutagenesis of MYO5A gene | CTD | PMID:9825669 more ... | N-methyl-N-nitrosurea | increases mutagenesis | ISO | RGD:731454 | 6480464 | Methylnitrosourea results in increased mutagenesis of MYO5A gene | CTD | PMID:10517996 PMID:17174358 | N-methyl-N-nitrosurea | increases mutagenesis | ISO | RGD:731454 | 6480464 | Methylnitrosourea results in increased mutagenesis of MYO5A gene | CTD | PMID:17174358 PMID:10517996 | paclitaxel | increases response to substance | ISO | RGD:731453 | 6480464 | MYO5A protein results in increased susceptibility to Paclitaxel | CTD | PMID:16734730 | paracetamol | affects expression | ISO | RGD:731454 | 6480464 | Acetaminophen affects the expression of MYO5A mRNA | CTD | PMID:17562736 | paracetamol | increases expression | ISO | RGD:731453 | 6480464 | Acetaminophen results in increased expression of MYO5A mRNA | CTD | PMID:22230336 | pirinixic acid | multiple interactions | ISO | RGD:731454 | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of MYO5A mRNA | CTD | PMID:19710929 | quercetin | increases expression | ISO | RGD:731453 | 6480464 | Quercetin results in increased expression of MYO5A protein | CTD | PMID:15221776 | resveratrol | multiple interactions | ISO | RGD:731453 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of MYO5A mRNA | CTD | PMID:19167446 | tamoxifen | increases expression | ISO | RGD:731453 | 6480464 | Tamoxifen results in increased expression of MYO5A protein | CTD | PMID:17098229 | tamoxifen | multiple interactions | ISO | RGD:731453 | 6480464 | [Tretinoin co-treated with Tamoxifen] results in increased expression of MYO5A protein | CTD | PMID:17098229 | tert-butyl hydroperoxide | increases expression | ISO | RGD:731453 | 6480464 | tert-Butylhydroperoxide results in increased expression of MYO5A mRNA | CTD | PMID:15336504 | trans-resveratrol | multiple interactions | ISO | RGD:731453 | 6480464 | [Coumestrol co-treated with resveratrol] results in decreased expression of MYO5A mRNA | CTD | PMID:19167446 | valproic acid | affects expression | ISO | RGD:731454 | 6480464 | Valproic Acid affects the expression of MYO5A mRNA | CTD | PMID:17292431 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Ontology Annotations
Molecular Pathway Annotations
Phenotype Annotations
Disease Annotations
Gene-Chemical Interaction Annotations
|
|
|
Gene Ontology Annotations
|
|
|
|
|
|
|
|
Molecular Pathway Annotations
Phenotype Annotations
|
|
References - curated
References - uncurated| PubMed | 11432975 |
| 1298991 | |
| 18311135 | |
| 18568366 | |
| 19214741 | |
| 19787448 | |
| 19812310 | |
| 21080055 | |
| 21349835 | |
| 21842169 | |
| 21985333 | |
| 22437832 |
RGD Disease Portals| Myo5a has been annotated in the following RGD Disease Portals. |
|||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
![]() |
| ||||||||
Comparative Map Data| Myo5a (Rattus norvegicus) |
|
|||||||||||||||||||||||||||||||||||
| MYO5A (Homo sapiens) |
|
|||||||||||||||||||||||||||||||||||
| Myo5a (Mus musculus) |
|
Position Markers| RH139301 |
|
QTLs in Region (RGSC Genome Assembly v3.4)| The following QTLs overlap with this region. | ![]() | Full Report | ![]() | CSV | ![]() | TAB | ![]() | Printer | ![]() | Gviewer |
Related Rat Strains
Nucleotide Sequences| RefSeq Acc Id: | NM_022178 | ||||||||||||||||||||
| RefSeq Status: | PROVISIONAL | ||||||||||||||||||||
| Type: | CODING | ||||||||||||||||||||
| Protein Acc Id: | NP_071514 | ||||||||||||||||||||
| Position: |
|
Protein Sequences| Protein RefSeqs | NP_071514 | (Get FASTA) |
| GenBank Protein | BAA88350 | (Get FASTA) |
| EDL77811 | (Get FASTA) | |
| EDL77812 | (Get FASTA) | |
| EDL77813 | (Get FASTA) | |
| Q9QYF3 | (Get FASTA) |
Strain Sequence Variants
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
External Database Links| Database | Acc Id | Source(s) |
| Entrez Gene | 25017 | ENTREZGENE |
| Germonline | ENSRNOG00000022968 | UniProtKB/Swiss-Prot |
| HomoloGene Group ID | 20100 | ENTREZGENE |
| InterPro | Dil_domain | UniProtKB/Swiss-Prot |
| Dilute | UniProtKB/Swiss-Prot | |
| IQ_CaM_bd_region | UniProtKB/Swiss-Prot | |
| Myosin_head_motor_dom | UniProtKB/Swiss-Prot | |
| IPI | IPI00214038 | UniProtKB/Swiss-Prot |
| KEGG Report | rno:25017 | ENTREZGENE, UniProtKB/Swiss-Prot |
| Pfam | DIL | UniProtKB/Swiss-Prot |
| Myosin_head | UniProtKB/Swiss-Prot | |
| PF00612 | UniProtKB/Swiss-Prot | |
| PRINTS | MYOSINHEAVY | UniProtKB/Swiss-Prot |
| PROSITE | DILUTE | UniProtKB/Swiss-Prot |
| PS50096 | UniProtKB/Swiss-Prot | |
| SMART | MYSc | UniProtKB/Swiss-Prot |
| SM00015 | UniProtKB/Swiss-Prot | |
| TIGR | TC206609 | |
| UniGene | Rn.44865 | ENTREZGENE |
| UniProt | MYO5A_RAT | UniProtKB/Swiss-Prot |
Nomenclature History| Date | Current Symbol | Current Name | Previous Symbol | Previous Name | Description | Reference | Status |
|---|---|---|---|---|---|---|---|
| 2009-12-15 | Myo5a | myosin VA | Myo5a | myosin Va | Nomenclature updated to reflect human and mouse nomenclature | 10779 | APPROVED |
| 2004-02-26 | Myo5a | myosin Va | Symbol and Name status set to approved | 2225 | APPROVED | ||
| 2002-06-10 | Myo5a | myosin 5a | Name updated | 1489 | PROVISIONAL | ||
| 2001-04-06 | Myo5a | Dilute-opisthotonus | Name withdran - does not match symbol | 101 | WITHDRAWN | ||
| 2001-04-06 | Myo5a | Myosin 5a | Name changed to match symbol | 101 | APPROVED |
RGD Curation Notes| Note Type | Note | Reference |
|---|---|---|
| gene_disease | deletions and decreased expression are detected in the ataxic dilute-opisthotonus rat | 61493 |
| gene_function | may function as a actin-dependent organelle transporter | 61493 |
| More on Myo5a | |
![]() |
Entrez Gene |
![]() |
Ensembl Gene |
![]() | Genome Browser |
![]() |
NCBI Map Viewer |
![]() |
Vista |
![]() |
Vista + UCSC |
| RGD Object Information | |
| RGD ID: | 3143 |
| Created: | 2000-05-25 |
| Species: | Rattus norvegicus |
| Last Modified: | 2013-04-16 |
| Status: | ACTIVE |
© Bioinformatics Program, HMGC at the Medical College of Wisconsin
RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.




